click here to return to homepage
 
  more Info

ELISAOsteoporosis Kits

Osteoporosis KitsOur Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine samples providing evidence of elevated bone resorption.


Osteoporosis Kits

     Osteomark NTx EIA Kits


All kits include the following:

  • 12 x 8 well strips with 
    
  • Sample diluent
          breakaway wells    
  •  Conjugate
  •  Controls and calibrators
    
  •  Wash buffer
  •  TMB substrate
    
  •  Adsorbent Solution
  •  Stop solution
                (for IgM kits)
  •  Directional insert
      


Featured Product

Osteomark NTx

Osteomark NTx assays are sensitive and specific assays that can be used to indicate subtle changes in levels of bone resorption.1-8 Osteomark NTx serum and urine assays provide a quantitative measurement of the cross-linked N-telopeptides of bone type I collagen (NTx). NTx is a specific biochemical indicator of bone resorption that is generated as a result of osteoclast activity on bone. The NTx molecule is specific to bone due to the unique amino acid sequence and orientation of the cross-linked alpha-2 (I) N-telopeptide.9

Osteomark NTx provides a dynamic indicator of the current level of bone resorption, shows significantly earlier response to therapy (with 3-6 months) and, when used in conjunction with bone mineral density (BMD), gives a more complete picture of bone status than either technology alone.10

Simple
Easy to use ELISA or Point of Care tests

Specific
NTx is a specific marker of bone resporption

Sensitive
Confirms patient response to antiresorptive therapy within a few months

Swift
Rapid determination of patient results


Clinical utility 

  • To monitor response to antiresorptive therapy in osteoporosis11
  • To determine probability for accelerated decrease in bone mass in postmenopausal women
  • To help assess the need to initiate antiresorptive therapy by predicting skeletal response (BMD)
  • To counsel patients about continuation of therapy


Features and Benefits

Urine

  • Standard ELISA format
  • Simple and convenient to perform
  • Requires no specialized equipment
  • Fast assay time, results available in less than 2 hours

 

Serum

  • Standard ELISA procedure
  • No creatinine testing or correction required
  • Fast assay time, results available in less than 2 hours
  • Reproducible results with good precision
  • Low within-patient variability

 


For more information, visit http://www.osteomark.com/

References

1. Garnero P, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79:1693-1700.
2. Gertz BJ, et al. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 1994; 9:135-142.
3. Rosen CJ, et al. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997; 82:1904-1910.
4. Gertz BJ, et al. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int. 1998; 63:102-106.
5. Scariano JK, et al. Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women. Bone 1998; 23:471-477.
6. Prestwood KM, et al. Low dose estrogen and calcium have an additive effect on bone resorption in older women. J Clin Endocrinol Metab 1999;84:179-183.
7. Clemens JD, et al. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 1997; 43:2058-2063.
8. Eastell R, et al. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000; 15-594-598.
9. Hanson DA, et al. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Min Res 1992; 7:1251-1258.
10. Miller P. Clinical interpretation and utility of bone densitometry. Osteoporosis: Diagnostic and therapeutic principles. 1996; 113-119.
11. Greenspan SL, et al. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Min Res. 1998; 13:1431-1438.

Ordering Information

Back to Top